Intellia Therapeutics (NTLA) CEO reports 34,146-share sell-to-cover tax sale

Rhea-AI Filing Summary

Intellia Therapeutics, Inc. President and CEO John M. Leonard, who is also a director, reported a mandatory sell-to-cover stock transaction. On January 5, 2026, he sold 34,146 shares of common stock at $9.21 per share to cover tax withholding obligations arising from the vesting of restricted stock units on January 1, 2026. The filing states this was not a voluntary trade. After this transaction, Leonard beneficially owned 1,013,339 common shares directly and an additional 58,415 common shares indirectly held by the John M. Leonard 2015 Irrevocable Trust.

Insider Trade Summary

Net Seller: 34,146 shares ($314,485)

Net Sell 2 txns

Insider LEONARD JOHN M

Role President and CEO

Sold 34,146 shs ($314K)

Type	Security	Shares	Price	Value
Sale	Common Stock	34,146	$9.21	$314K
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 1,013,339 shares (Direct); Common Stock — 58,415 shares (Indirect, By Trust)

Footnotes (1)

1. Represents a mandatory "sell-to-cover" transaction for the purpose of satisfying the reporting person's tax withholding obligation upon the vesting of RSUs on January 1, 2026, and does not represent a volitional trade by the Reporting Person. Shares held by the John M. Leonard 2015 Irrevocable Trust.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

LEONARD JOHN M

(Last) (First) (Middle)

C/O INTELLIA THERAPEUTICS, INC.

40 ERIE STREET; SUITE 130

(Street)

CAMBRIDGE MA 02139

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Intellia Therapeutics, Inc. [ NTLA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

3. Date of Earliest Transaction (Month/Day/Year)
01/05/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/05/2026		S(1)		34,146	D	$9.21	1,013,339	D
Common Stock								58,415	I	By Trust(2)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents a mandatory "sell-to-cover" transaction for the purpose of satisfying the reporting person's tax withholding obligation upon the vesting of RSUs on January 1, 2026, and does not represent a volitional trade by the Reporting Person.

2. Shares held by the John M. Leonard 2015 Irrevocable Trust.

	James Basta, attorney-in-fact	01/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did NTLA CEO John M. Leonard report?

He reported a mandatory sell-to-cover transaction in which 34,146 shares of Intellia Therapeutics common stock were sold on January 5, 2026 at $9.21 per share.

Why did NTLA's CEO sell 34,146 shares of stock?

The filing explains the sale was a mandatory sell-to-cover to satisfy John M. Leonards tax withholding obligation upon the vesting of RSUs on January 1, 2026, and it was not a volitional trade.

How many Intellia Therapeutics (NTLA) shares does John M. Leonard own after the sale?

Following the reported transaction, John M. Leonard beneficially owned 1,013,339 shares of common stock directly and 58,415 shares indirectly held by the John M. Leonard 2015 Irrevocable Trust.

How are the indirect NTLA shares held for John M. Leonard?

The filing notes that 58,415 common shares are held indirectly by the John M. Leonard 2015 Irrevocable Trust.

What role does John M. Leonard hold at Intellia Therapeutics (NTLA)?

John M. Leonard is identified as both a director and an officer, serving as President and CEO of Intellia Therapeutics, Inc.

Was the January 5, 2026 NTLA stock sale a discretionary trade by the CEO?

No. The filing states the transaction was a mandatory sell-to-cover for tax withholding related to RSU vesting and does not represent a volitional trade by John M. Leonard.